MAPK1 and breast carcinoma: Activation of the ERK/AKT pathway also phosphorylates or reprograms the ER, leading to chemoresistance to fulvestrant and the cyclin‐dependent kinase (CDK)4/6 inhibitor, palbociclib, in ER+ breast cancer.136, 137